Table 1Selection Criteria

PopulationPeople of all ages, in a community setting, who are taking multiple medications
InterventionQ1,2: Pharmacist-led medication reviews
ComparatorQ1,2: No medication review
Outcomes

Q1: Clinical utility (e.g., hospital admissions, deprescribing of medication(s), medication adherence, health markers or outcomes [e.g., blood pressure, HbA1c, LDL/HDL, INR, use of inhalers], and safety [e.g., death, adverse drug reactions])

Q2: Cost-effectiveness (e.g., cost per health benefit gained, cost per preventable adverse drug reaction, cost per disability adjusted life year avoided)

Study DesignsQ1, 2: Health Technology Assessments, Systematic Reviews, Meta-Analyses, Economic Evaluations

HbA1c = glycated haemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; INR = international normalized ratio.

From: Pharmacist-Led Medication Reviews: A Review of Clinical Utility and Cost-Effectiveness

Cover of Pharmacist-Led Medication Reviews: A Review of Clinical Utility and Cost-Effectiveness
Pharmacist-Led Medication Reviews: A Review of Clinical Utility and Cost-Effectiveness [Internet].
Shane A, Argáez C.
Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.